COVID-19 感染幸存者肾上腺与甲状腺功能正常
在 Imperial College NHS Healthcare Trust 开展的前瞻性观察研究纳入 70 例 ≥18 岁、COVID-19 诊断后至少 3 个月的患者,行 250 µg 静脉短效 Synacthen 试验与甲状腺功能评估。所有患者 Synacthen 后峰值皮质醇 ≥450 nmol/L,提示肾上腺储备充足;皮质醇与甲状腺功能在疾病严重程度、地塞米松治疗史及疲劳与否间均无差异。结论为 COVID-19 后 ≥3 个月肾上腺与甲状腺功能保留,持续疲劳不能由这两项内分泌功能改变解释。
要点
- COVID-19 后 ≥3 个月患者 Synacthen 后峰值皮质醇均 ≥450 nmol/L,肾上腺储备充足。
- 基线与峰值皮质醇不随 COVID-19 严重程度或地塞米松治疗史而变化。
- 疲劳组(n=44)与无疲劳组(n=26)的皮质醇及甲状腺功能无差异。
核心结论
- COVID-19 表现后 ≥3 个月肾上腺与甲状腺功能保留,持续疲劳不能由肾上腺或甲状腺功能改变解释。
研究设计与样本
- 前瞻性观察研究,在 Imperial College NHS Healthcare Trust 临床研究机构开展,纳入 70 例 ≥18 岁、COVID-19 诊断后至少 3 个月的患者。
- 参与者在上午 8:00-9:30 进行研究访视,接受 250 µg 静脉短效 Synacthen 试验及甲状腺功能评估。
主要发现
- 所有患者 Synacthen 后峰值皮质醇 ≥450 nmol/L,符合肾上腺储备充足。
- 基线与峰值血清皮质醇不随疾病严重程度或 COVID-19 期间地塞米松治疗史而不同。
- 疲劳患者(n=44)与无疲劳患者(n=26)在 Synacthen 前后皮质醇、甲状腺功能检查或甲状腺状态上均无差异。
临床怎么用
- COVID-19 后持续疲劳患者不应默认归因于肾上腺或甲状腺功能异常,需评估其他病因。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The COVID-19 pandemic continues to exert an immense burden on global health services. Moreover, up to 63% of patients experience persistent symptoms, including fatigue, after acute illness. Endocrine systems are vulnerable to the effects of COVID-19 as many glands express the ACE2 receptor, used by the SARS-CoV-2 virion for cellular access. However, the effects of COVID-19 on adrenal and thyroid gland function after acute COVID-19 remain unknown. OBJECTIVE: Our objectives were to evaluate adrenal and thyroid gland function in COVID-19 survivors. METHODS: A prospective, observational study was undertaken at the Clinical Research Facility, Imperial College NHS Healthcare Trust, including 70 patients ≥18 years of age, at least 3 months after diagnosis of COVID-19. Participants attended a research study visit (8:00-9:30 am), during which a short Synacthen test (250 µg IV bolus) and thyroid function assessments were performed. RESULTS: All patients had a peak cortisol ≥450 nmol/L after Synacthen, consistent with adequate adrenal reserve. Basal and peak serum cortisol did not differ according to disease severity or history of dexamethasone treatment during COVID-19. There was no difference in baseline or peak cortisol after Synacthen or in thyroid function tests, or thyroid status, in patients with fatigue (n = 44) compared to those without (n = 26). CONCLUSION: Adrenal and thyroid function ≥3 months after presentation with COVID-19 was preserved. While a significant proportion of patients experienced persistent fatigue, their symptoms were not accounted for by alterations in adrenal or thyroid function. These findings have important implications for the clinical care of patients after COVID-19.
引用
- Clarke SA, Phylactou M, Patel B, et al. Normal Adrenal and Thyroid Function in Patients Who Survive COVID-19 Infection. J Clin Endocrinol Metab. 2021. PMID: 34008009. doi:10.1210/clinem/dgab349
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。